These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 14671159)

  • 21. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
    Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis.
    Giltay EJ; Gooren LJ; Emeis JJ; Kooistra T; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1396-403. PubMed ID: 10807760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
    Seaman HE; de Vries CS; Farmer RD
    Hum Reprod; 2003 Mar; 18(3):522-6. PubMed ID: 12615818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of cross-sex hormone treatment on cortical thickness in transsexual individuals.
    Zubiaurre-Elorza L; Junque C; Gómez-Gil E; Guillamon A
    J Sex Med; 2014 May; 11(5):1248-61. PubMed ID: 24617977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.
    van Kesteren P; Lips P; Gooren LJ; Asscheman H; Megens J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):347-54. PubMed ID: 9578826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjectures concerning cross-sex hormone treatment of aging transsexual persons.
    Gooren L; Lips P
    J Sex Med; 2014 Aug; 11(8):2012-9. PubMed ID: 24775178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Morbidity in transsexual patients with cross-gender hormone self-treatment].
    Becerra Fernández A; de Luis Román DA; Piédrola Maroto G
    Med Clin (Barc); 1999 Oct; 113(13):484-7. PubMed ID: 10604171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
    Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
    Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
    Spitzer WO
    J Obstet Gynaecol Can; 2003 Dec; 25(12):1011-8. PubMed ID: 14663535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
    Ott J; Kaufmann U; Bentz EK; Huber JC; Tempfer CB
    Fertil Steril; 2010 Mar; 93(4):1267-72. PubMed ID: 19200981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical and hormonal evaluation of transsexual patients: a longitudinal study.
    Meyer WJ; Webb A; Stuart CA; Finkelstein JW; Lawrence B; Walker PA
    Arch Sex Behav; 1986 Apr; 15(2):121-38. PubMed ID: 3013122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term hormone effects in transsexuals.
    Slabbekoorn D; van Goozen SH; Megens J; Gooren LJ; Cohen-Kettenis PT
    Psychoneuroendocrinology; 1999 May; 24(4):423-47. PubMed ID: 10341369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-sex hormone administration changes pain in transsexual women and men.
    Aloisi AM; Bachiocco V; Costantino A; Stefani R; Ceccarelli I; Bertaccini A; Meriggiola MC
    Pain; 2007 Nov; 132 Suppl 1():S60-S67. PubMed ID: 17379410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
    Asscheman H; Gooren LJ; Eklund PL
    Metabolism; 1989 Sep; 38(9):869-73. PubMed ID: 2528051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical use of antiandrogens in the female].
    Moltz L; Schwartz U; Hammerstein J
    Gynakologe; 1980 Mar; 13(1):1-17. PubMed ID: 6299908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
    J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen treatment effects on cognition, memory and mood in male-to-female transsexuals.
    Miles C; Green R; Hines M
    Horm Behav; 2006 Dec; 50(5):708-17. PubMed ID: 16884726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.